NICE National Institute for Health and Care Excellence

NICE guidance

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)

Technology appraisal guidance
Published: 14 December 2011
Last updated: 29 March 2017

www.nice.org.uk/guidance/ta240

Contents

This guidance is partially replaced by TA439.

Advice

NICE is unable to make a recommendation about the use in the NHS of panitumumab with 5 fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This because Amgen did not provide an evidence submission. They consider that there is not enough evidence to provide an evidence submission for this appraisal.

Information

If NHS organisations wish to consider panitumumab with 5 fluorouracil, folinic acid and irinotecan (FOLFIRI) for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

Update information

March 2017: The population covered by the marketing authorisation for panitumumab changed from 'patients with wild-type KRAS metastatic colorectal cancer' to 'patients with wild-type RAS metastatic colorectal cancer'.

ISBN: 978-1-4731-2442-4